Global Morpho Pharma

La Chapelle-sur-Erdre,  France 
  • Booth: 278

Highly reliable partner for GMP radiopharmaceuticals

Created in 2018, Global Morpho Pharma SAS aims at developing, distributing and selling radionuclides under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. The company intends to become one of the major and global suppliers of pharmaceutical grade radionuclides for the pharmaceutical industry and will primarily focus on:

  • Nca Lutetium-177

Non-carrier added Lutetium-177 is a beta emitter (electrons) with an intermediate range of action in body tissues. Its action spectrum, combined with the absence of long half-life radioactive impurities, makes it an effective isotope for the treatment of a wide range of cancers when coupled with vector molecules targeting specific cancer cell biomarkers.

  • Actinium-225

Actinium-225 is a short-range alpha emitter (helium nucleus) that deposits a large amount of energy into the surrounding tissues. It is therefore very effective in damaging the double strand of the DNA helix in cancer cells, resulting in effective destruction of these cells. Once attached to a vector selectively targeting a cancer cell, it will mainly deposit its energy in the direct vicinity of these cells.

More information:

Come visit us at booth 157 

For Technical Support with this webpage, please contact support.